Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Shares Outstanding (Weighted Average) (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Shares Outstanding (Weighted Average) for 6 consecutive years, with $62.0 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 15.28% to $62.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $62.0 million through Dec 2025, up 15.28% year-over-year, with the annual reading at $62.0 million for FY2025, 15.28% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $62.0 million at Janux Therapeutics, roughly flat from $61.9 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $62.0 million in Q4 2025, with the low at $1.1 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $43.4 million, with a median of $42.5 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) skyrocketed 20197.6% in 2021, then rose 0.95% in 2022.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $23.5 million in 2021, then soared by 76.24% to $41.5 million in 2022, then rose by 6.14% to $44.0 million in 2023, then rose by 22.12% to $53.8 million in 2024, then grew by 15.28% to $62.0 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $62.0 million, $61.9 million, and $61.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.